Catalyst Wire Dossier Catalyst Wire Dossier

CGF166

· Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CGF166, covering 2021-03-30 to 2021-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss [Phase 1, Phase 2]

See pricing